Cargando…

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old

We compared efavirenz pharmacokinetic (PK) parameters in children with tuberculosis (TB)/human immunodeficiency virus (HIV) coinfection on and off first-line antituberculosis therapy to that in HIV-infected children. Children 3 to 14 years old with HIV infection, with and without TB, were treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwara, Awewura, Yang, Hongmei, Antwi, Sampson, Enimil, Anthony, Gillani, Fizza S., Dompreh, Albert, Ortsin, Antoinette, Opoku, Theresa, Bosomtwe, Dennis, Sarfo, Anima, Wiesner, Lubbe, Norman, Jennifer, Alghamdi, Wael A., Langaee, Taimour, Peloquin, Charles A., Court, Michael H., Greenblatt, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325194/ https://www.ncbi.nlm.nih.gov/pubmed/30397066 http://dx.doi.org/10.1128/AAC.01657-18

Ejemplares similares

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

In-Clinic Adolescent Peer Group Support for Engagement in Sub-Saharan Africa: A Feasibility and Acceptability Trial
por: Barker, David, et al.
Publicado: (2019)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Pharmacokinetic Interactions between the Hormonal Emergency Contraception, Levonorgestrel (Plan B), and Efavirenz
por: Carten, Monica L., et al.
Publicado: (2012)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital
por: Saavedra, Adriana, et al.
Publicado: (2017)

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas
por: Pienaar, Elsje, et al.
Publicado: (2018)

Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia
por: Getahun, Muluwork, et al.
Publicado: (2022)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis
por: Chen, Suting, et al.
Publicado: (2017)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
por: Johnston, Jenna, et al.
Publicado: (2019)

Microencapsulated Isoniazid-Loaded Metal–Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs
por: Fernández-Paz, Cristina, et al.
Publicado: (2021)

Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients
por: Archampong, Timothy N. A., et al.
Publicado: (2016)

Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases
por: Vadwai, Viral, et al.
Publicado: (2012)

Severe efavirenz associated neurotoxicity: A retrospective cohort study
por: Arnab, Priyadarshini, et al.
Publicado: (2023)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
por: Sistanizad, Mohammad, et al.
Publicado: (2011)

Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
por: Su, Qiang, et al.
Publicado: (2021)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment
por: Mthiyane, Thuli, et al.
Publicado: (2020)

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
por: Gausi, Kamunkhwala, et al.
Publicado: (2020)

Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double hydroxide based nanocomposites
por: Saifullah, Bullo, et al.
Publicado: (2016)

Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso
por: Miotto, Paolo, et al.
Publicado: (2009)

Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis
por: Zhang, Mengmeng, et al.
Publicado: (2022)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA
por: Heysell, Scott K., et al.
Publicado: (2013)

Validation of the FluoroType MTBDR Assay for Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates
por: Hillemann, Doris, et al.
Publicado: (2018)

Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection
por: Dasht Bozorg, Behnam, et al.
Publicado: (2019)

Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age
por: López-Ramos, Maria Goretti, et al.
Publicado: (2023)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge
por: Havlicek, Juliane, et al.
Publicado: (2018)

Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis
por: Sirous, Mehrandokht, et al.
Publicado: (2018)

Successful rapid oral desensitization for dual hypersensitivity to isoniazid and rifampin while treating central nervous system tuberculosis
por: Roy, Moni, et al.
Publicado: (2018)

Detecting rifampin and isoniazid resistance in Mycobacterium tuberculosis direct from patient sputum using an automated integrated system
por: Colman, Rebecca E., et al.
Publicado: (2022)

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients
por: Swart, Marelize, et al.
Publicado: (2016)

Evaluation of a High-Intensity Green Fluorescent Protein Fluorophage Method for Drug- Resistance Diagnosis in Tuberculosis for Isoniazid, Rifampin, and Streptomycin
por: Yu, Xia, et al.
Publicado: (2016)

A Rapid Assessing Method of Drug Susceptibility Using Flow Cytometry for Mycobacterium tuberculosis Isolates Resistant to Isoniazid, Rifampin, and Ethambutol
por: Lee, Sun-Kyoung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ftbh0vloskf6bec2ckoslh0i31